Update in Oncology
Authors: Julie R. Brahmer
Journal: Annals of Internal Medicine (2005)

Updates18 October 2005Update in OncologyJulie R. Brahmer, MDJulie R. Brahmer, MDFrom The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, Maryland.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-143-8-200510180-00009 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail This Update in Oncology focuses on 4 common tumors in patients: prostate cancer, non–small-cell lung cancer, breast cancer, and colorectal cancer. The hot topic in 2004 for prostate cancer was docetaxel. The hot topic for non–small-cell lung cancer was pemetrexed, which was approved for second-line use in 2004, and epidermal growth factor receptor (EGFR) mutations. The hot topic in 2004 for breast cancer was the use of aromatase inhibitors for adjuvant treatment. Finally, the hot topics for colorectal cancer were the trials studying bevacizumab and cetuximab.Prostate CancerFor localized prostate cancer, the treatment paradigm is local treatment, radiation, and ...References1. Sinibaldi VJ, Carducci MA, Moore-Cooper S, Laufer M, Zahurak M, Eisenberger MA. Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma. Cancer. 2002;94:1457-65. [PMID: 11920502] CrossrefMedlineGoogle Scholar2. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, et al. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A. 2004;101:13306-11. [PMID: 15329413] CrossrefMedlineGoogle Scholar3. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304:1497-500. [PMID: 15118125] CrossrefMedlineGoogle Scholar4. Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S, Squire J, et al. Erlotinib in lung cancer—molecular and clinical predictors of outcome. N Engl J Med. 2005;353:133-44. [PMID: 16014883] CrossrefMedlineGoogle Scholar5. Fisher B, Dignam J, Bryant J, DeCillis A, Wickerham DL, Wolmark N, et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst. 1996;88:1529-42. [PMID: 8901851] CrossrefMedlineGoogle Scholar6. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003;349:1793-802. [PMID: 14551341] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, Maryland.Disclosures: Honoraria: sanofi-aventis, AstraZeneca; Grants received: AstraZeneca, Wyeth.Corresponding Author: Julie R. Brahmer, MD, 1650 Orleans Street, Room G94, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21231-1000. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 18 October 2005Volume 143, Issue 8Page: 587-592KeywordsAromatase inhibitorsBreast cancerCancer treatmentChemotherapyColorectal cancerLung and intrathoracic tumorsMutationProstate cancer ePublished: 18 October 2005 Issue Published: 18 October 2005 CopyrightCopyright © 2005 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...